Microsoft selbst warnt vor der Verwendung von Internet Explorer, da er nicht mehr den neuesten Web- und Sicherheitsstandards entspricht. Wir können daher nicht garantieren, dass die Seite im Internet Explorer in vollem Umfang funktioniert. Nutze bitte Chrome oder Firefox.

Better Buy: 10x Genomics vs. DermTech

TheMotleyFool

0 0

Better Buy: 10x Genomics vs. DermTechPhoto, wide shot, wide-angle lens, Clinical research organization, Blue hour, twilight, cool, ISO1200, slow shutter speed, photo by David Maisel: https://img.theapi.app/temp/0e9d087d-988e-4397-b7cf-6049e2776769.png

If you are looking to invest in companies that aim to provide disruptive technology to the healthcare sector, there can be plenty of intriguing options. While some of those may lack a solid foundation to build a high-quality business on, 10x Genomics (NASDAQ: TXG) and DermTech (NASDAQ: DMTK) don't suffer from that issue, and each is well worth your consideration.

Both have immense potential, but which stock is a better buy today? Two Motley Fool contributors battle it out to answer this question.

Image Source: Getty Images.

Source Fool.com

Like: 0

TXG

Teilen